Stock PSYG PSYENCE GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Psyence Group Inc.

Equities

PSYG

CA74449Q1063

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 03:43:26 2024-04-22 pm EDT 		5-day change 1st Jan Change
0.03 CAD +20.00% Intraday chart for Psyence Group Inc. +20.00% -40.00%
Mar. 26 Psyence Group Closes Strategic Restructuring of Its Non-Clinical Business MT
Mar. 26 An undisclosed buyer completed the acquisition of Mind Health Ltd and Psyence Uk Group Ltd from Psyence Group Inc.. CI

Business Summary

Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its federally licensed ISO22000 facility in Southern Africa. The Company’s divisions include Psyence Production, Psyence Therapeutics and Psyence Function. Psyence Therapeutics develops natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Production operates federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world. Psyence Function is focused on the development, distribution and sale of over-the-counter functional mushroom nutraceutical products.

Managers

Managers TitleAgeSince
Jody Aufrichtig FOU
 Founder 51 94-03-25
Katherine Murphy IRC
 Investor Relations Contact - -
Taryn Vos LAW
 General Counsel - 20-12-31
Tony Budden PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Alan Friedman BRD
 Director/Board Member 52 21-03-02
Jody Aufrichtig FOU
 Founder 51 94-03-25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 139,106,226 133,745,581 ( 96.15 %) 0 96.15 %

Shareholders

NameEquities%Valuation
Alan Friedman
1.952 %
2,601,460 1.952 % 72 841 $
Jody Aufrichtig
1.311 %
1,746,934 1.311 % 48 914 $
Neil Maresky
0.9142 %
1,218,523 0.9142 % 34 119 $
Warwick Corden-Lloyd
0.2816 %
375,322 0.2816 % 10 509 $
Marvin Singer
0.1598 %
212,998 0.1598 % 5 964 $
Adri Botha
0.0198 %
26,400 0.0198 % 739 $
Christopher Bull
0.000000 %
0 0.000000 % - $

Holdings

NameEquities%Valuation
Psyence Biomedical Ltd.
37.34%
 5,000,000 37.34% 5,700,000 $

Company contact information

Psyence Group, Inc.

121 Richmond Street West Penthouse Suite, 1300

M5H 2K1, Toronto

+

http://www.psyence.com
address Psyence Group Inc.(PSYG)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PSYENCE GROUP INC. Stock Psyence Group Inc.
-40.00% 3.05M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PSYG Stock
  4. Company Psyence Group Inc.